Enveric Biosciences, Inc. (ENVB) Stock Analysis & Investment Frameworks
Enveric Biosciences, Inc. (ENVB) stock analysis on Invetso. Review Enveric Biosciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Enveric Biosciences, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Enveric Biosciences, Inc. Key Financial Metrics
- Market Cap: $862682.00
- Revenue: $N/A
- ROE: -168.05%
- ROIC: -107.99%
- Dividend Yield: N/A
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Enveric Biosciences, Inc. Investment Frameworks
Invetso analyzes Enveric Biosciences, Inc. (ENVB) across the following frameworks:
- Enveric Biosciences, Inc. 10Y Growth Potential
- Enveric Biosciences, Inc. Scenario Analysis
- Enveric Biosciences, Inc. Risks & Opportunities
- Enveric Biosciences, Inc. Economic Moat
- Enveric Biosciences, Inc. Business Model
- Enveric Biosciences, Inc. Management
- Enveric Biosciences, Inc. SWOT Analysis
- Enveric Biosciences, Inc. Porter's 5 Forces
- Enveric Biosciences, Inc. PESTLE Analysis
- Enveric Biosciences, Inc. ESG Analysis
